A Combination of Methylation and Protein Markers is Capable of Detecting Gastric Cancer Detection by Combined Markers

Abstract

<b>Aim:</b> This study aimed to validate a combination of <i>mSEPT9</i>, <i>mRNF180</i> and CA724 for gastric cancer (GC) detection. <b>Patients & methods:</b> The performance of <i>mSEPT9</i>, <i>mRNF180</i> and CA724 was examined in a prospective cohort study with 518 participants (151 with GC, 56 with atrophic gastritis, 87 with other gastrointestinal diseases and 224 with no evidence of disease). <b>Results:</b><i>mSEPT9</i>, <i>mRNF180</i> or CA724 alone detected 48.3, 37.1 and 43.1% of GC, respectively. The combination of <i>mSEPT9</i> and <i>mRNF180</i> detected 60.3% of GC, and the combination of all three markers detected 68.6% of GC. The detection sensitivity of <i>mSEPT9</i> and <i>mRNF180</i> was significantly higher for gastric body and in elder subjects. <i>mSEPT9</i> was correlated with poorer GC survival. <b>Conclusion:</b> The combination of <i>mSEPT9</i>, <i>mRNF180</i> and CA724 was adequately sensitive for GC detection. The blood <i>mSEPT9</i> was predictive for GC prognosis.